Je kan informatie over je locatie aan je Tweets toevoegen, bijvoorbeeld je stad of exacte locatie, via het web en applicaties van derden. Je kan altijd de locatiegeschiedenis van je Tweets verwijderen. Meer informatie
Combine this with the Yu et al. paper in @ScienceMagazine comparing different DNA-based platforms in non-human primate models, showing that full-length S (same as INO-4800) appears to be the best immunogen and is protective:
https://science.sciencemag.org/content/early/2020/05/19/science.abc6284 …
4/7
Note, animals did not* develop sterilizing immunity - there was a ~3-log drop in virus titers after challenge in vaccinated animals vs controls. From the Chandrashekar et al. paper in @ScienceMagazine we see a 5-log diff. after natural infection:
https://science.sciencemag.org/content/early/2020/05/19/science.abc4776 …
5/7
Seeing this data - and the MERS data - I'm optimistic that Inovio might have a shot at a viable DNA vaccine (which would be a first). Yes, we need trials, human data, challenge models, and know longevity of response, but it's early days. 6/7
Does this mean we'll soon have a DNA-based SARS-CoV-2 vaccine? Probably not - too many failure points to navigate and still too little data for an unproven platform, BUT, that would be my conclusion for any current vaccine candidate. Overall, I see this as encouraging news. 7/7
Sidenote on this study - it isn't surprising at all and we really can't conclude that SARS-CoV-2 infection (always) leads to protection. The NHP model combined with short timeline (~1 month) does not allow us to make general conclusions about human immunity to SARS-CoV-2. 5a/7
Twitter is mogelijk overbelast of ondervindt een tijdelijke onderbreking. Probeer het opnieuw of bekijk de Twitter-status voor meer informatie.
